Db. Bylund et al., VASCULAR ALPHA-ADRENOCEPTORS - FROM THE GENE TO THE HUMAN, Canadian journal of physiology and pharmacology, 73(5), 1995, pp. 533-543
Adrenoceptors can be subdivided into three major types, the alpha(1)-,
alpha(2)-, and beta-adrenoceptors. Each of these types can be further
subdivided into three subtypes, based on pharmacological characterist
ics. Molecular cloning techniques have supported this subclassificatio
n. Recent data now suggest that cr-adrenoceptor subtypes identified by
pharmacological and molecular techniques correspond well, although sp
ecies orthologs of several adrenoceptor subtypes have been identified.
The secondary structure of the adrenoceptors has been elucidated and
correlated with their interaction with second messenger molecules. alp
ha(1)-Adrenoceptors, beta-adrenoceptors, and alpha(2)-adrenoceptors me
diate their actions through stimulation of inositol phosphate release,
stimulation of adenylate cyclase, and inhibition of adenylate cyclase
, respectively. Site-directed mutagenesis and the preparation of chime
ric receptors have located the site of receptor - second messenger int
eraction to the third intracellular loop for each of these adrenocepto
rs. While subtypes of each of these classes all interact with the same
second messenger, studies with recombinant alpha(2)-adrenoceptors sho
w subtype-related differences in receptor second messenger interaction
. Multiple cr-adrenoceptor subtypes are expressed in vascular smooth m
uscle and are involved in various aspects of blood vessel function, in
cluding contraction, cellular growth, and proliferation. Various physi
ological factors can selectively influence responses to a particular s
ubtype, and the relative roles of each subtype can vary between vascul
ar beds and along an individual blood vessel as its caliber changes. F
unctional studies in blood vessels suggest the presence of additional
alpha-adrenoceptor subtypes not yet identified via molecular technique
s. Optimization of the therapeutic profile of an alpha-adrenoceptor an
tagonist may be possible via enhancement of selectivity for a particul
ar subtype or by design of a specific profile of affinity for the indi
vidual subtypes.